Who Paid My Doc
Allen Stark
Psychiatry Lake Oswego, OR Medical Doctor
NPI 1427125806 CMS profile 110105
340 Oswego Pointe Dr, Suite 205, Lake Oswego, OR 97034
General payments
$2,932
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Allen Stark of Lake Oswego, OR is reported in the CMS Open Payments database as having received $2,932 across 150 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 83rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $224 | 11 | |
| 2022 | General | $691 | 31 | |
| 2021 | General | $865 | 37 | |
| 2020 | General | $609 | 39 | |
| 2019 | General | $543 | 32 |
Beside peers
- Allen Stark
- Psychiatry median
- Middle half of Psychiatry
- National median
In program year 2025, general payments to Allen Stark were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.
Show as a table
| Year | Allen Stark | Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $543 | $184 | $59–$605 | $163 |
| 2020 | $609 | $119 | $36–$372 | $114 |
| 2021 | $865 | $143 | $43–$576 | $132 |
| 2022 | $691 | $153 | $50–$590 | $149 |
| 2023 | $224 | $170 | $56–$651 | $160 |
| 2024 | $0 | $179 | $57–$673 | $164 |
| 2025 | $0 | $180 | $58–$685 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
143
Drug cost
$4,062
Branded share of claims
55.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | Brand | 28 | $1,160 | |
| Desvenlafaxine Succinate Er Desvenlafaxine Succinate | Brand | 13 | $851 | |
| Venlafaxine Hcl Er Venlafaxine Hcl | Brand | 19 | $607 | |
| Bupropion Xl Bupropion Hcl | Brand | 19 | $542 | |
| Trazodone Hcl | Generic | 36 | $484 | |
| Duloxetine Hcl | Generic | 13 | $314 | |
| Zaleplon | Generic | 15 | $104 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.
Records
150 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Psychiatry in Oregon
Practitioners in the same specialty and state, ranked by reported value.
All Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in Oregon
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.